http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20060125756-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac3e787a6871df4284213bb52de1883d |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P27-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-395 |
| filingDate | 2003-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa8aea75aabe1a196105e8e6c61bd9d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0cb19c93b6918532acc87bf0ad8944a9 |
| publicationDate | 2006-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20060125756-A |
| titleOfInvention | Use of vinpocetin for the prevention and treatment of complications, especially hearing-related complications that occur with epilepsy |
| abstract | The present invention relates to the use of vinpocetin and its derivatives, which can occur while maintaining the same effect on the treatment of epilepsy and its complications. The results obtained indicate that vinpocetin inhibits all alterations of RATC waves accompanied by cortical interstitial activity during seizures and post-seizure periods in two in vivo epilepsy experimental models. It also shows that it inhibits the characteristic changes of induced EEG and significant hearing loss. The findings indicate that the ability of vinpocetin as an antiepileptic drug has no secondary adverse effects. |
| priorityDate | 2006-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.